2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Ovarian Neoplasms
6
Advanced Solid Tumours
5
Squamous Cell Carcinoma of Head and Neck
4
Small Cell Lung Carcinoma
4
Uterine Cervical Neoplasms
3
Neoplasms
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Glioblastoma
3
Fallopian Tube Neoplasms
3
Uterine Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma
2
Hematologic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Advanced Malignant Solid Neoplasm
2
Vaginal Neoplasms
1
Urinary Bladder Neoplasms
1
Triple-negative Metastatic Breast Cancer
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Rhabdomyosarcoma
1
Interventions
Injections
27
Carboplatin
18
Docetaxel
14
pembrolizumab
13
Paclitaxel
12
Bevacizumab
10
durvalumab
8
Nivolumab
8
Cisplatin
8
Fluorouracil
7
Pemetrexed
6
Oxaliplatin
6
Leucovorin
6
trifluridine tipiracil drug combination
5
toripalimab
5
tislelizumab
5
linifanib
5
Capecitabine
5
zimberelimab
4
talazoparib
4
olaparib
4
fludarabine
4
Panobinostat
4
Itraconazole
4
Irinotecan
4
Gemcitabine
4
Everolimus
4
tremelimumab
3
sotorasib
3
sintilimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumors
×
adavosertib
×
Clear all
NCT05008913
2022-09-06
ADME
AstraZeneca
Phase 1
Terminated
2 enrolled